Loading stock data…
TLSI
$4.39+0.07 (+1.62%)
Market ClosedLast close May 1
TriSalus Life Sciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TriSalus Life Sciences, Inc. in the Healthcare sector is trading at $4.39. The stock is currently 45% below its 52-week high of $7.95, remaining 12.0% below its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why TLSI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.39
Potential Upside
5%
Whystock Fair Value$4.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$284.35M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
115.85%
Volume
Today's trading volume
61,804
Recent News
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the […]
TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of TriSalus Life Sciences, Inc.'s Q4 2025 earnings call
TriSalus Life Sciences Q4 Earnings Call Highlights
TriSalus Life Sciences (NASDAQ:TLSI) reported fourth-quarter and full-year 2025 results that management characterized as “strong,” driven by growth in its TriNav product suite and broader adoption of its Pressure-Enabled Drug Delivery (PEDD) platform beyond liver-directed procedures. Revenue growth
TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
TriSalus Life Sciences Inc (TLSI) reports a 60% revenue increase and strategic growth plans, despite facing operational losses and delayed clinical data releases.
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? Ms. Szela will provide an overview of the company's fourth quarter results and strategy for the balance of the year, and then David will review the financial results for the quarter in detail.